Detailed Opportunity Analysis
🚀 High-Probability Biotech Setups
Week of April 13–17, 2026
Catalyst-driven trades built for momentum and asymmetric upside.
Strategy:
• Small sizing (1–2%)
• Enter near support
• Cut losers fast
• Scale winners into strength
• Small sizing (1–2%)
• Enter near support
• Cut losers fast
• Scale winners into strength
📊 Catalyst Overview
🧬 Why These Matter
TVTX: Rare kidney disease company. Approval = immediate revenue shift.
IDYA: Precision oncology. Biomarker targeting increases success odds.
MGTX: Gene therapy platform. Strong durability potential.
ASMB: Backed by Gilead. Large unmet HSV-2 market.
KURA: Combo oncology strategy. High upside if validated.
📈 Trade Setups
TVTX
Entry: $28.5–29.5
Stop: $27.5
Target: $35 / $42
Upside: +30–60%
IDYA
Entry: $29.5–31
Stop: $28
Target: $40 / $50
Upside: +60%+
MGTX
Entry: $8.5–9
Stop: $7.5
Target: $16 / $23
Upside: +150%+
ASMB
Entry: $28–29
Stop: $26
Target: $35 / $45
Upside: +45–60%
KURA
Entry: $8.5
Stop: $7.5
Target: $16 / $30+
Upside: +200%+
⚠️ Risk & Disclaimer
• These are high-volatility biotech trades
• Outcomes are binary (win big / lose fast)
• Always use risk management
• Outcomes are binary (win big / lose fast)
• Always use risk management
This content is for educational purposes only and is not financial advice. Trading involves risk, including loss of capital. Probabilities are estimates based on public data and are not guarantees. Always do your own research and consult a financial professional before making investment decisions.
Comments
Post a Comment